Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 7/20 | 0.54 |
| ▸ | NOS3 | P29474 | 6/20 | 0.54 |
| ▸ | NOS1 | P29475 | 5/20 | 0.54 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ELANE | P08246 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12810690 | 0.85 | TDP1 (0.42) | NOS2NOS3NOS1TDP1NR4A2 | |
| SCHEMBL23999695 | 0.77 | NOS3 (0.54) | NOS2NOS3NOS1CYP1A2CYP2C19 | |
| SCHEMBL12411157 | 0.76 | HRH4 (0.51) | NOS2NOS3NOS1HRH4TDP1 | |
| SCHEMBL31324837 | 0.71 | — | — | |
| SCHEMBL94111 | 0.71 | — | — | |
| SCHEMBL1425069 | 0.71 | ALOX15 (0.38) | TDP1LMNAALDH1A1 | |
| SCHEMBL10024341 | 0.69 | TDP1 (0.55) | TDP1TRPM8LMNANPSR1ALDH1A1 | |
| SCHEMBL21227309 | 0.69 | CRHBP (0.50) | HRH4TDP1LMNACYP1A2CYP2C19 | |
| Bromide SCHEMBL5755666 | 0.69 | NOS2 (0.95) | NOS2NOS3NOS1 | |
| SCHEMBL10204248 | 0.68 | NOS2 (0.54) | NOS2NOS3NOS1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219927-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-07-13 | — | — | US | disclosed |
| US-20230183226-A1 | AKT3 MODULATORS | Georgiamune Inc. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183226-A1 | AKT3 MODULATORS | AKT3, AKT2, MTOR | NOS2 3170/4885NOS3 612/4885NOS1 3493/4885 |
| US-20230219927-A1 | AKT3 MODULATORS | AKT3, AKT2, PIK3CA | NOS2 3467/4885NOS3 817/4885NOS1 3333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.